{
  "alleleExist":false,
  "dataVersion":"v4.5",
  "diagnosticImplications":[
    {
      "abstracts":[],
      "alterations":[
        "Oncogenic Mutations"
      ],
      "description":"",
      "levelOfEvidence":"LEVEL_Dx3",
      "pmids":[
        "28302137",
        "21390126"
      ],
      "tumorType":{
        "children":{},
        "code":"DLBCLNOS",
        "color":"LimeGreen",
        "id":490,
        "level":5,
        "mainType":{
          "id":null,
          "name":"Mature B-Cell Neoplasms",
          "tumorForm":"LIQUID"
        },
        "name":"Diffuse Large B-Cell Lymphoma, NOS",
        "parent":"MBN",
        "tissue":"Lymphoid",
        "tumorForm":"LIQUID"
      }
    },
    {
      "abstracts":[],
      "alterations":[
        "Oncogenic Mutations"
      ],
      "description":"",
      "levelOfEvidence":"LEVEL_Dx3",
      "pmids":[
        "24362818",
        "25713363"
      ],
      "tumorType":{
        "children":{},
        "code":"FL",
        "color":"LimeGreen",
        "id":286,
        "level":5,
        "mainType":{
          "id":null,
          "name":"Mature B-Cell Neoplasms",
          "tumorForm":"LIQUID"
        },
        "name":"Follicular Lymphoma",
        "parent":"MBN",
        "tissue":"Lymphoid",
        "tumorForm":"LIQUID"
      }
    }
  ],
  "diagnosticSummary":"",
  "geneExist":true,
  "geneSummary":"CREBBP, a tumor suppressor and transcriptional co-activator, is frequently inactivated in hematologic malignancies.",
  "highestDiagnosticImplicationLevel":"LEVEL_Dx3",
  "highestFdaLevel":null,
  "highestPrognosticImplicationLevel":null,
  "highestResistanceLevel":null,
  "highestSensitiveLevel":null,
  "hotspot":true,
  "lastUpdate":"10/05/2020",
  "mutationEffect":{
    "citations":{
      "abstracts":[],
      "pmids":[
        "21390126"
      ]
    },
    "description":"The CREBBP S1680del mutation is located in the histone acetyltransferase (HAT) domain of the CREBBP protein. This mutation has been found in lymphomas, among other cancers (PMID: 21390126). In vitro studies have demonstrated that this mutation is likely inactivating as measured by decreased HAT activity compared to wildtype (PMID: 21390126).",
    "knownEffect":"Likely Loss-of-function"
  },
  "oncogenic":"Likely Oncogenic",
  "otherSignificantResistanceLevels":[],
  "otherSignificantSensitiveLevels":[],
  "prognosticImplications":[],
  "prognosticSummary":"",
  "query":{
    "alteration":"S1680del",
    "alterationType":null,
    "consequence":"inframe_deletion",
    "entrezGeneId":1387,
    "hgvs":"16:g.3731323_3731325del",
    "hugoSymbol":"CREBBP",
    "id":null,
    "proteinEnd":1681,
    "proteinStart":1680,
    "referenceGenome":"GRCh38",
    "svType":null,
    "tumorType":null
  },
  "treatments":[],
  "tumorTypeSummary":"",
  "variantExist":true,
  "variantSummary":"The CREBBP S1680del alteration is likely oncogenic.",
  "vus":false
}